Lipid nanoparticles (LNPs) play an important role in mRNA vaccines against COVID-19. In
addition, many preclinical and clinical studies, including the siRNA-LNP product, Onpattro® …

The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …

Due to the fact that mRNA technology allows the production of diverse vaccines and
treatments in a shorter time frame and with reduced expense compared to conventional …

RNA-based gene therapy requires therapeutic RNA to function inside target cells without
eliciting unwanted immune responses. RNA can be ferried into cells using non-viral drug …

Conspectus Lipid nanoparticles (LNPs) are a type of lipid vesicles that possess a
homogeneous lipid core. These vesicles are widely used in small-molecule drug and …

The expanding applications of nonviral genomic medicines in the lung remain restricted by
delivery challenges. Here, leveraging a high-throughput platform, we synthesize and screen …

Abstract mRNA vaccines have emerged as a revolutionary tool to generate rapid and
precise immune responses against infectious diseases and cancers. Compared with …

Messenger RNA (mRNA) has received great attention in the prevention and treatment of
various diseases due to the success of coronavirus disease 2019 (COVID‐19) mRNA …

An inhalable platform for messenger RNA (mRNA) therapeutics would enable minimally
invasive and lung-targeted delivery for a host of pulmonary diseases. Development of lung …

Systemic messenger RNA (mRNA) delivery to organs outside the liver, spleen, and lungs
remains challenging. To overcome this issue, we hypothesized that altering nanoparticle …